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Objective: After positive experimental results were obtained with the FloWatch-R-
PAB (EndoArt S.A., Lausanne, Switzerland), an implantable device for pulmonary
artery banding with telemetric control, it was tested in a prospective, multicenter
clinical trial.
Methods: From June to September 2002, 6 patients with a mean age of 10.6 months
(1-31 months) and a mean weight of 6.5 kg (3.5-11 kg) underwent pulmonary artery
banding with the implantation of the FloWatch-R-PAB device through median
sternotomy (4 patients) or left thoracotomy (2 patients). The diagnoses were the
following: univentricular heart (2 patients), complete atrioventricular septal defect
(2 patients), ventricular septal defect (1 patient), and multiple ventricular septal
defects with double aortic arch (1 patient). The associated procedures were atrio-
septostomy with cardiopulmonary bypass (2 patients), closure of patent ductus
arteriosus (2 patients), and division of double aortic arch (1 patient).
Results: In a mean follow-up of 7 months (6-9 months), there were no early or late
deaths, reoperations, or device-related complications. A mean of 5 regulations per
patient (range 2-14) were required to adjust the tightening of the pulmonary artery
banding, 50% (15/30) within the first postoperative week, 20% (6/30) during the
second week, and 30% (9/30) within 8 months after surgery. In 70% (21/30) of the
cases, the regulation was required to further narrow the pulmonary artery, and in
30% (9/30) of the cases, the regulation was required to release the pulmonary artery.
Conclusions: The initial trial confirmed the adequate functioning of the FloWatch-
R-PAB device as telemetrically adjustable pulmonary artery banding. Repeated
pulmonary artery banding adjustments, dictated by the clinical need in all patients
even weeks after surgery, were accomplished without need for reoperation or
invasive procedures. In children requiring pulmonary artery banding, the therapeutic
strategies can be expanded by this promising technology. This device should be
particularly indicated in patients with transposition of the great arteries requiring left
ventricular retraining.
The indication for pulmonary artery banding (PAB) is currently lim-ited by several factors:1. Difficulty in determining the optimal band, because minorchanges in diameter have a large impact on blood flow andpressure gradient across the band site.2. Influence of several perioperative variables with mutual inter-
ference related to general anesthesia with positive pressure
ventilation and chest opening, particularly with thoracotomy.1
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3. Age-related variability of the ventricular adaptive re-
sponse, particularly in “functionally” univentricular
hearts2 and transposition of the great arteries requiring
retraining of a low pressure left ventricle in view of
arterial switch operation.3
4. Difficulty in sufficiently tightening the banding in
children with pulmonary hypertension.
5. Flow adjustment in children with congenital heart
defects with increased pulmonary blood flow, with or
without cyanosis, in which the PAB is successful in
controlling the distal pressure but overflow persists.
6. Frequent need for repeated operations to adjust the
band perimeter, including children outgrowing a band-
ing that is rapidly becoming too tight.
7. Long periods of intensive respiratory or pharmaco-
logic interventions to control the pulmonary blood
flow.3
8. Frequent need for a reconstruction of the pulmonary
artery at the moment of the conventional debanding
for surgical repair.
To overcome these difficulties, several attempts have
been made to find an adjustable PAB that allows external
regulation during the hours or days after the surgical pro-
cedure.4-19 A MEDLINE research for “adjustable PAB”
revealed 16 different techniques reported within the last 10
years. However, none of these techniques resulted in a
device allowing a precise, long-term, noninvasive adjust-
ment of pulmonary blood flow in both ways, with repeated
narrowing and releasing of the pulmonary artery.
Therefore, we decided to perform an experimental study
in mini-pigs with the FloWatch-R-PAB (EndoArt S.A.,
Lausanne, Switzerland), an implantable, telemetrically con-
trolled, battery-free device (Figure 1) that allows repeated
progressive occlusion and reopening of the device through a
remote control at the required percentage of occlusion.20
The change in the adjustable area is obtained by a piston
driven by an incorporated electric micromotor. The concave
form of the adjustable area was chosen so that during
compression the area changes but the perimeter of the
pulmonary artery remains unchanged, which is optimal for
long-term use (ie, reopening after several weeks of pulmo-
nary artery compression). The adjustable area in the fully
open position corresponds to a PAB with a perimeter of 30
mm, and in the fully closed position to a PAB with a
perimeter of 23 mm. The adjustment is performed through
an external control unit that delivers the energy and com-
mands (through the antenna) to drive the micro-engine. The
size of the device is 26  18  18 mm.
Because of the positive long-term results of the experi-
mental study with this new adjustable PAB,21,22 we decided
to perform a prospective, multicenter clinical trial.
Methods
After approval by the institutional ethical committee of each
hospital, informed consent was obtained from the parents or legal
guardians of all children enrolled in the clinical trial.
From June to September 2002, 6 patients with a mean age of
10.6 months (range 1-31 months) and a mean body weight of 6.5
kg (range 3.5-11 kg) underwent PAB with the FloWatch-R-PAB
device implantation. The technical characteristics of the device
have been reported in detail.20-22
The diagnosis was univentricular heart in 2 patients (hypoplas-
tic mitral valve and intact atrial septum in 1 patient and right
isomerism, dextrocardia, total anomalous pulmonary venous con-
nection, and patent ductus arteriosus in 1 patient), complete atrio-
ventricular septal defect in 2 patients (left ventricular dominance
and patent ductus arteriosus in 1 patient), isolated ventricular
septal defect in 1 patient, and multiple ventricular septal defects
and double aortic arch in 1 patient. All infants presented with
systolic pulmonary artery pressure at systemic levels. The 2 chil-
dren who came to our observation after infancy at 19 and 31
months of age with complete atrioventricular septal defect and
isolated ventricular septal defect, respectively, presented with el-
evated pulmonary vascular resistance nonresponsive to the routine
pulmonary vasodilators, precluding first-stage repair.
The implantation of the FloWatch-R-PAB device was per-
formed through median sternotomy (4 patients) or left thoracot-
omy (2 patients) according to the need for associated surgical
procedures and the surgeon’s preference.
The surgical technique for the implantation of the FloWatch-
R-PAB device was exactly the same as for conventional PAB, with
minimal dissection to encircle the pulmonary artery with the clip
of the FloWatch-R-PAB device in an open position. Then the
device was clipped, and the pericardium and chest were closed in
routine fashion.
Associated procedures were atrioseptostomy with cardiopul-
monary bypass in 2 patients (1 patient with associated division of
patent ductus arteriosus), closure of patent ductus arteriosus in 1
patient, and division of double aortic arch in 1 patient.
The intraoperative and postoperative device-related data were
recorded, in particular with regard to the clinical follow-up, need
Figure 1. The FloWatch-R-PAB (EndoArt S.A., Lausanne, Switzer-
land) device in clipped and unclipped position.
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for telemetric PAB adjustments, reoperations, or device-related
complications.
Results
The implantation of the device was easy in all cases, with
the entire surgical procedure lasting less than 40 minutes in
the 2 patients not requiring associated procedures. The
reduced time needed for PAB obtained with the Flo-
Watch-R-PAB device is justified by the possibility of
telemetric adjustment of the tightening of the PAB after
chest closure.
All children were extubated within the first 24 hours after
surgery. The median stay in the intensive care unit was 1
day, with 4 patients staying 1 day, 1 patient staying 3 days,
and a neonate with Down syndrome and association of a
major upper airway problem requiring endoscopic supra-
glottoplasty staying 29 days.
There were no early or late deaths, reoperations, or
device-related complications in a mean follow-up of 7
months (range 6-9 months).
After the first telemetric regulation of the FloWatch-R-
PAB device on the same day of surgery, a mean of 5
regulations per patient (range 2-14) were required to adjust
the tightening of the PAB to the clinical needs; 50% (15/30)
of telemetric regulations were required within the first post-
operative week, 20% (6/30) during the second week, and
30% (9/30) between 3 weeks and 8 months after surgery. In
all cases, tightening and releasing of the pulmonary artery
were performed under control with Doppler echocardiogra-
phy, with the same correspondence between the percentage
of occlusion and trans-banding pressure gradient as ob-
served in the experimental study.22 Figure 2 shows the
unusual postoperative chest x-ray film.
In 70% (21/30) of cases, the regulation was required to
further narrow the pulmonary artery, and in 30% (9/30) of
cases, the regulation was required to release the pulmonary
artery. In 2 cases, the telemetric release of the pulmonary
artery was required on an emergency basis because of
arterial oxygen desaturation and bradycardia. We appreci-
ated the capability of obtaining full release of the pulmonary
artery within less than 60 seconds allowed by the device.
During the relatively short follow-up period, only the
child with isolated ventricular septal defect underwent sur-
gical repair 3 months after the implantation of the Flo-
Watch-R-PAB device; the procedure was uneventful, with
uncomplicated device removal and without need for pulmo-
nary artery reconstruction.
Discussion
The main technical problem encountered in PAB is the
difficulty in determining the optimum perimeter of the band.
Both turbulent and viscous losses are highly dependent on
the radius of the vessel; therefore, a minor change in diam-
eter has a large impact on blood flow and pressure gradient
across the band site.
Moreover, the effects of the banding on pulmonary artery
pressure and flow are influenced by clinical variables with
mutual interference: heart rate and contractility, arterial PO2
and PCO2, acid-base status, hematocrit, and balance between
systemic and pulmonary resistance.1 Substantial changes
occur to all these variables, particularly within the first
hours and days after surgery, with particular instability
within the first few hours or days after the operation.1
It is therefore very difficult to predict the effectiveness of
a PAB with the band applied in an almost instantaneous
Figure 2. Postoperative chest x-ray film in the anteroposterior (A) and lateral (B) views showing the device in
place.
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fashion and the decision about the adequacy of the tighten-
ing based on few parameters (systemic and pulmonary
artery pressure, systemic oxygen saturation, and expired
CO2) followed by only a short interval before the chest
closure.1
Because of all these reasons, surgical operations may be
required to adjust the band perimeter, or a long period with
intensive respiratory and pharmacologic interventions may
be needed to control the pulmonary blood flow.3
The need for adjustable PAB has been confirmed by the
extensive experimental and clinical research performed in
different institutions4-19 that has not procured a reliable
device capable of noninvasively narrowing and releasing
the pulmonary artery days or weeks after surgery.
With all these problems in mind, we adopted the idea of
a device allowing PAB through a fast-track surgical proce-
dure, with the effective possibility of telemetric control of
the pulmonary blood flow and the trans-banding pressure
gradient, even a long time after surgical implantation. In our
experimental study, we demonstrated the adequate function-
ing of the device with the capability of narrowing and
releasing the pulmonary artery by telemetric control up to
14 months after implantation.21,22
Another advantage of this technique observed in our
experimental study is the maintenance of normal morphol-
ogy and histology of the pulmonary artery wall in conjunc-
tion with the narrowing, allowing for full distension of the
pulmonary artery after removal of the device, without ste-
nosis and therefore without pulmonary artery reconstruc-
tion.22 In our relatively short clinical experience, only 1
child underwent FloWatch-R-PAB device removal because
of the surgical repair, and even if the interval was short (3
months), there was no need for any procedure to fully dilate
the pulmonary artery.
The main clinical advantages of PAB with the FloWatch-
R-PAB device, forecasted as potential advantages when we
reported the experimental results21,22 and the first clinical
application23 (and confirmed by the initial observations in
this multicenter clinical trial), are the following: fast-track
surgical procedure, effective control of pulmonary blood
flow, no banding-related reoperations, and simplified post-
operative course.
As a consequence of these advantages, a reduction of
mortality and morbidity can be expected when comparing a
substantial number of patients with this new approach with
a homogeneous group of patients with conventional band-
ing. We realize that the major limit of our clinical trial is the
absence of prospective randomization versus the conven-
tional treatment, but in consideration of the experimental
data and the problems encountered in conventional banding,
as soon as the FloWatch-R-PAB device became clinically
available we all agreed that children requiring a PAB should
be able to take advantage of this already available tech-
nique.
Nevertheless, we reviewed the data of the patients who
underwent conventional PAB at Centre Hospitalier Univer-
sitaire Vaudois, Lausanne, Switzerland, before the clinical
availability of the FloWatch-R-PAB device. Among 11
consecutive children, there was an incidence of 45.5% (5/
11) of required reoperations to adjust the tightening of the
band, a mean duration of mechanical ventilation of 9.7 days
(range 2-28 days), and a mean stay in the intensive care unit
of 19.4 days (range 4-41 days) (unpublished data; Corno,
2002). These data are worse than the initial clinical obser-
vations in our trial, even if this historical group included a
substantial number of patients requiring left ventricular
retraining because of late referral for arterial switch.24
If future clinical studies with FloWatch-R-PAB device
implantation confirm our initial results and clinical benefits,
this device will represent a major change in the management
of children requiring PAB, particularly for the most com-
plex pathophysiologic situations, such as univentricular
hearts requiring preparation for total cavopulmonary con-
nection and transposition of the great arteries requiring left
ventricular retraining because of late referral. The size of the
currently available device limits the clinical application to
children weighing 15 to 20 kg, and therefore a larger size
needs to be developed for older children and adolescents,
particularly for left ventricular retraining.
The cost of this evolving technology is unknown because
currently the device is only available for the multicenter
clinical trial. When it becomes commercially available, the
price will need to be balanced against the effective reduc-
tion of costs brought about by the shorter stay in the inten-
sive care unit and hospital and the reduced number of
reoperations.
Finally, the indications for PAB could be expanded to
adapt the therapeutic strategies to this promising technol-
ogy.
Addendum
Since the submission of this article, the multicenter clinical
trial has been extended to 14 patients weighing between 3.5
and 20 kg. There have been no deaths or device-related
reoperations. Four patients have undergone intracardiac re-
pair with device removal, and none required a reconstruc-
tion of the pulmonary artery.
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Discussion
Dr Duke E. Cameron (Baltimore, Md). Thank you, Dr. Corno, for
this fine presentation and for sharing your article with me before
the meeting. You and your group have presented the first clinical
series of a totally implantable, remote-controlled, bidirectionally
adjustable PAB with very encouraging results.
An adjustable band has long been sought by some congenital
heart surgeons, who as a group all know that every PAB is perfect
in the operating room and every band is either too loose or too tight
by the time the child is back in the intensive care unit. The
optimum band parameter is thus a moving target. So adjustability
has obvious appeal.
You have shown that your device works, that it is safe, and that
adjustability persists for approximately 1 year, but the follow-up is
brief, and having said that adjustability is desirable, we are still
uncertain if this relatively expensive and complex device provides
a substantial clinical advantage in most patients over a single
shoestring of siliconized Teflon. I suspect that further experience
will reflect on this, but I might predict that most patients with PAB
do not require multiple adjustments.
You mentioned in your article that reinterventions for tighten-
ing or loosening with conventional banding were required in 45%
of patients in your institution, which I would think would be a bit
high. In fact, most infants are well served by a single application
of a band without adjustment and then early progression to either
definitive total correction or a cavopulmonary shunt.
I expect the greatest use of this device will be seen in that
ever-diminishing group of patients who need left ventricular re-
training for a staged arterial switch or perhaps in a small select
group who are undergoing experimental treatments for Eisen-
menger’s. In both of these groups there is a definite need for slow,
progressive tightening of the band over time.
I have 3 questions. First, could you give us a rough idea of the
cost of this device?
Second, although I meant to ask you why this band causes less
morphologic and histologic distortion than a conventional band, I
see that I think you have explained that the band flattens the PA
rather than crimps it. But I wonder if you could address a different
question. The device itself is fairly bulky, and I could imagine in
a small infant, in certain anatomic subtypes with a pulmonary
artery directly posterior to the aorta, that the device may be
difficult to fit in the mediastinum without compressing adjacent
structures.
And finally, do you really see this being used in all patients, or
do you suspect that there are just certain patients for whom the
adjustability is highly desirable?
Finally, do you have some thoughts about applications of this
device outside of cardiac surgery?
Dr Corno. Thank you very much, Dr. Cameron, for your very
kind comments. To answer your first question about the price, the
device will be commercially available at the beginning of June in
countries without Food and Drug Administration regulations, and
the price should be in the range of a pacemaker price. Of course,
you can easily say that a polytetrafluoroethylene or Teflon band is
much cheaper, but I believe that the price should be balanced
against the reduced stay in the intensive care unit and hospital,
mechanical ventilation time, and cost of reoperations and compli-
cations. So this should pay for the price of the device.
Regarding the question of the morphology of the pulmonary
artery, when we removed the device, and this was up to 6 months
or even 14 months after the implant, there was a full reexpansion
of the pulmonary artery in all 16 mini-pigs of the experimental
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study. We also performed a histology in all of them, and there was
normal morphology of the pulmonary artery. We have no expla-
nation but only speculation to offer, and that is because the
pulmonary artery, instead of being exposed to a circular restriction
as in a conventional band, is squeezed, as you have seen, with a
banana shape, and this, by reducing the cross-sectional area but not
the circumference, is adequate to reduce the pressure and the flow
distal to the device but not enough to induce a fibrosis. These
observations have been confirmed in the clinical experience. So
far, none of the patients have required reconstruction of the pul-
monary artery after device removal.
Regarding the size, you are right, it is quite bulky, but the
length is 26 mm, and the other 2 dimensions are 18 mm each. We
implanted this device in the smallest mini-pig of 3.2 kg. The
smallest patient was also 3.2 kg. We did not observe any com-
pression of coronaries or lung in any of the mini-pigs or patients,
provided that the box of the device was left on the other side of the
aorta, of course. We suggest, anyway, that the device be applied in
children weighing 3.5 kg and not smaller than that.
Regarding the last comment (if this device is indicated in all
patients), we started this study only because very complex cases
are referred to our tertiary center. We are pushing toward an early
repair, so we do not perform any more banding in regular or simple
ventricular septal defect or atrioventricular septal defects.
In the period before this device was available, we were faced
with a very complex group of patients with transposition of great
arteries and intact ventricular septum, referred for left ventricular
retraining before arterial switch between 6 months and 2 years of
age, univentricular heart at 1 or 2 years of age with pulmonary
hypertension, or ventricular septal defect or atrioventricular septal
defect at 3, 4, or more years of age with high pulmonary vascular
resistance not responsive to conventional vasodilators. I believe
this group is very difficult to manage with conventional banding;
at least in our experience, the postoperative course was a night-
mare. Particularly for the univentricular heart or left ventricular
retraining (recently published in Cardiology in the Young), we had
to go back to adjust the banding or we had the patient on mechan-
ical ventilation in the intensive care unit for a long period of time.
Dr Renato S. Assad (Sao Paulo, Brazil). First, I want to
congratulate your group for pursuing the research and develop-
ment on a very ingenious adjustable PAB device. Since 1991, we
have been studying reversible PAB in young goats to assess
subpulmonary ventricle retraining. The prototype used in our ex-
periments, similar to our previous prototype described in an article
published last year in The Journal of Thoracic and Cardiovascular
Surgery, is a silicone-made PAB hydraulic cuff system (Silimed
Inc, Rio de Janeiro, Brazil). The main difference is that the
banding ring is a smaller C-shape flat tape, less than 2 mm (thick)
 6 mm (width). Its outer surface consists of 1-mm rigid silicone,
which keeps it from deforming. The inner surface has a deformable
layer of silicone, which expands (compressing the lumen of the
vessel) according to the volume injected into a circular reservoir
made of self-sealing silicone, in which the base includes a ceramic
plate. This auto-sealing button is implanted subcutaneously and
permits precise inflation or deflation of the banding ring percuta-
neously in young goats.
My main concern is related to the cost-benefit ratio. Our device
should cost much less than a pacemaker, and it is disposable. I was
wondering how much the FloWatch-R-PAB device would cost
compared with our adjustable hydraulic cuff system? Second, the
way it compresses the lumen of the pulmonary trunk is elliptical
rather than circular. In addition, it takes too much room around the
pulmonary artery. I would like to know if the change in the
pulmonary trunk shape imposes any initial gradient after placing a
loose device?
Dr Corno. Thank you for your questions. Of course I was
aware of your device, first because I read the article, and second
because you gave me a sample 2 years ago in another meeting, and
that is why I started to study our system. I believe we need a really
adjustable device that is able to not only narrow but also release
the pulmonary artery, which is not feasible, to my knowledge, with
any other device. We demonstrated we can reopen the pulmonary
artery even 14 months after the implant, and no other device is able
to do that.
I agree with you about the problem of the cost, but again, if the
intensive care unit stay can be reduced a few days, this will pay the
price for the device.
Regarding the size, as I told you, there is a certain space
occupation, but we never had any compression of any vital struc-
ture with any of the devices in experimental or clinical application.
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